Tumor bed boost integration during whole breast radiotherapy: A review of the current evidence

Pierfrancesco Franco; Domenico Cante; Piera Sciacero; Giuseppe Girelli; Maria Rosa La Porta; Umberto Ricardi

doi:10.1159/000369845

Tumor bed boost integration during whole breast radiotherapy: A review of the current evidence

Pierfrancesco Franco
, Domenico Cante
, Piera Sciacero
, Giuseppe Girelli
, Maria Rosa La Porta
, Umberto Ricardi

Research output: Contribution to journal › Review article › peer-review

Abstract

Radiation therapy delivered with hypofractionation, which involves the delivery of a higher dose per fraction in fewer fractions (generally with a lower total nominal dose) over a shorter overall treatment time, is an established therapeutic option at least for a selected group of early breast cancer patients after breast-conserving surgery. Optimal delivery of the tumor bed boost dose in terms of timing, fractionation, and total dose whenever a hypofractionated schedule is employed has yet to be established. We herein present a review of the current evidence on the role of boost integration in whole breast radiotherapy.

Original language	English
Pages (from-to)	44-49
Number of pages	6
Journal	Breast Care
Volume	10
Issue number	1
DOIs	https://doi.org/10.1159/000369845
Publication status	Published - 6 Apr 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adjuvant whole breast radiotherapy
Breast cancer
Concomitant boost
Hypofractionation
IGRT
IMRT
Simultaneous integrated boost

Access to Document

10.1159/000369845

Cite this

@article{8fe4e3a871dd4f7ab3e1d804e46be81b,

title = "Tumor bed boost integration during whole breast radiotherapy: A review of the current evidence",

abstract = "Radiation therapy delivered with hypofractionation, which involves the delivery of a higher dose per fraction in fewer fractions (generally with a lower total nominal dose) over a shorter overall treatment time, is an established therapeutic option at least for a selected group of early breast cancer patients after breast-conserving surgery. Optimal delivery of the tumor bed boost dose in terms of timing, fractionation, and total dose whenever a hypofractionated schedule is employed has yet to be established. We herein present a review of the current evidence on the role of boost integration in whole breast radiotherapy.",

keywords = "Adjuvant whole breast radiotherapy, Breast cancer, Concomitant boost, Hypofractionation, IGRT, IMRT, Simultaneous integrated boost",

author = "Pierfrancesco Franco and Domenico Cante and Piera Sciacero and Giuseppe Girelli and \{La Porta\}, \{Maria Rosa\} and Umberto Ricardi",

note = "Publisher Copyright: {\textcopyright} 2015 S. Karger GmbH, Freiburg.",

year = "2015",

month = apr,

day = "6",

doi = "10.1159/000369845",

language = "English",

volume = "10",

pages = "44--49",

journal = "Breast Care",

issn = "1661-3791",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Tumor bed boost integration during whole breast radiotherapy

T2 - A review of the current evidence

AU - Franco, Pierfrancesco

AU - Cante, Domenico

AU - Sciacero, Piera

AU - Girelli, Giuseppe

AU - La Porta, Maria Rosa

AU - Ricardi, Umberto

PY - 2015/4/6

Y1 - 2015/4/6

N2 - Radiation therapy delivered with hypofractionation, which involves the delivery of a higher dose per fraction in fewer fractions (generally with a lower total nominal dose) over a shorter overall treatment time, is an established therapeutic option at least for a selected group of early breast cancer patients after breast-conserving surgery. Optimal delivery of the tumor bed boost dose in terms of timing, fractionation, and total dose whenever a hypofractionated schedule is employed has yet to be established. We herein present a review of the current evidence on the role of boost integration in whole breast radiotherapy.

AB - Radiation therapy delivered with hypofractionation, which involves the delivery of a higher dose per fraction in fewer fractions (generally with a lower total nominal dose) over a shorter overall treatment time, is an established therapeutic option at least for a selected group of early breast cancer patients after breast-conserving surgery. Optimal delivery of the tumor bed boost dose in terms of timing, fractionation, and total dose whenever a hypofractionated schedule is employed has yet to be established. We herein present a review of the current evidence on the role of boost integration in whole breast radiotherapy.

KW - Adjuvant whole breast radiotherapy

KW - Breast cancer

KW - Concomitant boost

KW - Hypofractionation

KW - IGRT

KW - IMRT

KW - Simultaneous integrated boost

UR - https://www.scopus.com/pages/publications/84926284167

U2 - 10.1159/000369845

DO - 10.1159/000369845

M3 - Review article

SN - 1661-3791

VL - 10

SP - 44

EP - 49

JO - Breast Care

JF - Breast Care

IS - 1

ER -

Tumor bed boost integration during whole breast radiotherapy: A review of the current evidence

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this